Introduction The upper respiratory tract is a major route of infection for COVID-19 and other
respiratory diseases. Thus, it appears logical to exploit the nose as administration site to …

Clinically manifested resistance of bacteria to antibiotics has emerged as a global threat to
society and there is an urgent need for the development of novel classes of antibacterial …

Objectives Feline infectious peritonitis (FIP) is a serious disease that arises due to feline
coronavirus infection. The nucleoside analogues remdesivir and GS-441524 can be …

The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …

Remdesivir is one of the most attractive options for patients with hypoxemic respiratory
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …

The COVID‐19 pandemic continues to pose a substantial threat to human lives and is likely
to do so for years to come. Despite the availability of vaccines, searching for efficient small …

Prolonged, low-dose glucocorticoids (GCs) have shown the highest efficacy among
pharmacological and non-pharmacological treatments for COVID-19. Despite the World …

Summary Background Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …

This review aims to provide an overview of the synthetic strategies employed for generating
modifications within the sugar backbone of nucleoside analogs. We have focused our …